Skip to content

A Multicenter, Open Label, To Evaluate The Efficacy And Satisfaction Of Patrex® In Men With Erectile Dysfunction.

A Multicenter, Open Label, High Dose (100mg) Rapid Titration Study, To Evaluate The Efficacy And Satisfaction Of Patrex® (Sildenafil Citrate) In Men With Erectile Dysfunction In Mexico.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00468650
Enrollment
117
Registered
2007-05-03
Start date
2007-06-30
Completion date
2008-02-29
Last updated
2021-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction

Brief summary

A multicenter open label study to assess the efficacy of sildenafil rapid dose titration to 100 mg in men with erectile dysfunction, based on the Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF) questionnaire.

Interventions

DRUGsildenafil citrate

Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Documented Clinical diagnosis of Erectile Dysfunction (ED) by International Index of Erectile Function (IIEF) Erectile Function (EF) Domain score less than or equal to 25. * Subjects must be in a stable relationship

Exclusion criteria

* Subject with resting sitting hypotension (BP \<90/50 mmHg) or hypertension (BP\>170/110 mmHg) and orthostatic hypotension. * Subjects receiving any PDE (Phosphodiesterase)-5 inhibitors within 4 weeks prior to the date of screening. * Subjects with severe hepatic impairment, a known history of retinitis pigmentare. * Subjects with significant cardiovascular disease in the last 3 months (per medical history.

Design outcomes

Primary

MeasureTime frameDescription
International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Baseline to Week 6 Last Observation Carried Forward (LOCF)Week 6 LOCFIIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 & 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.

Secondary

MeasureTime frameDescription
International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2Week 4 and Week 6IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 & 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.
International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From BaselineWeek 2, Week 4 and Week 6IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.
International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2Week 4 and Week 6IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.
International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From BaselineWeek 2, Week 4 and Week 6IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2Week 4 and Week 6IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From BaselineWeek 2, Week 4, and Week 6IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.
International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2Week 4 and Week 6IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.
International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From BaselineWeek 2, Week 4 and Week 6IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2Week 4 and Week 6IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
Quality of Erection Questionnaire (QEQ): Total Score - Change From BaselineWeek 2, Week 4, and Week 6QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.
Quality of Erection Questionnaire (QEQ): Total Score- Change From Week 2Week 4 and Week 6QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.
Sexual Experience Questionnaire (Sex-Q): Erection Domain - Change From BaselineWeek 2, Week 4 and Week 6Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.
Sexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2Week 4 and Week 6Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.
Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From BaselineWeek 2, Week 4, and Week 6Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome
Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2Week 4 and Week 6Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome
Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From BaselineWeek 2, Week 4, and Week 6Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.
Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2Week 4 and Week 6Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From BaselineWeek 2, Week 4 and Week 6Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to Question 1 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 1 \[Were you able to achieve at least some erection (some enlargement of the penis)?\] = Yes) / (number of occasions where Question 1 was answered Yes or No)
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2Week 4 and Week 6Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to Question 1 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 1 \[Were you able to achieve at least some erection (some enlargement of the penis)?\] = Yes) / (number of occasions where Question 1 was answered Yes or No)
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From BaselineWeek 2, Week 4 and Week 6Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 2 \[Were you able to insert your penis into your partner's vagina?\] = Yes) / (number of occasions where SEP Question 2 was answered Yes or No).
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2Week 4 and Week 6Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 2 \[Were you able to insert your penis into your partner's vagina?\] = Yes) / (number of occasions where SEP Question 2 was answered Yes or No).
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From BaselineWeek 2, Week 4 and Week 6Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2Week 4 and Week 6Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From BaselineWeek 2, Week 4 and Week 6Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 4 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 4 \[Were you satisfied with the hardness of your erection?\] = Yes) / (number of occasions where SEP Question 4 was answered Yes or No).
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2Week 4 and Week 6Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 4 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 4 \[Were you satisfied with the hardness of your erection?\] = Yes) / (number of occasions where SEP Question 4 was answered Yes or No).
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From BaselineWeek 2, Week 4 and Week 6Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 5 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 5 \[Were you satisfied with this sexual encounter?\] = Yes) / (number of occasions where SEP Question 5 was answered Yes or No)
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2Week 4 and Week 6Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 5 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 5 \[Were you satisfied with this sexual encounter?\] = Yes) / (number of occasions where SEP Question 5 was answered Yes or No)
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From BaselineWeek 2, Week 4, and Week 6Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Q3 based on attempts with sexual stimulation (SS): 100\* (number of attempts with SS where SEP Q3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2Week 4 and Week 6Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Q3 based on attempts with sexual stimulation (SS): 100\* (number of attempts with SS where SEP Q3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)
Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From BaselineWeek 2, Week 4 and Week 6Mean change: mean change at each visit minus mean at baseline. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)
Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2Week 4 and Week 6Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)
Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineWeek 2, Week 4 and Week 6Mean change: mean change at each visit minus mean at baseline. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)
Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Week 4 and Week 6Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)
Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineWeek 2, Week 4 and Week 6Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (3= hard enough for penetration \[but not completely hard\]) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)
International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6Week 2, Week 4 and Week 6IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 & 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.
Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineWeek 2, Week 4 and Week 6Mean change: mean change at each visit minus mean at baseline. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)
Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Week 4 and Week 6Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)
Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineWeek 2, Week 4 and Week 6Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (hard enough for penetration \[but not completely hard\]) or 4 (completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)
Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Week 4 and Week 6Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (hard enough for penetration \[but not completely hard\]) or 4 (completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)
Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Week 4 and Week 6Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (3= hard enough for penetration \[but not completely hard\]) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)

Countries

Mexico

Participant flow

Pre-assignment details

Eligible subjects had to have at least 2 attempts at sexual intercourse during the 2 week screening phase to begin the sildenafil citrate 50mg treatment at baseline.

Participants by arm

ArmCount
Open Label Sildenafil Citrate
Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.
117
Total117

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up4
Overall StudyProtocol Violation1
Overall StudyWithdrawal by Subject2

Baseline characteristics

CharacteristicOpen Label Sildenafil Citrate
Age, Continuous53.3 years
STANDARD_DEVIATION 11
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
117 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
33 / —
serious
Total, serious adverse events
0 / 117

Outcome results

Primary

International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Baseline to Week 6 Last Observation Carried Forward (LOCF)

IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 & 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.

Time frame: Week 6 LOCF

Population: Modified intent to treat (MITT) population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, last assessment collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureValue (MEAN)Dispersion
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Baseline to Week 6 Last Observation Carried Forward (LOCF)10.96 score on scaleStandard Deviation 5.19
Comparison: Primary hypothesis to be tested is whether there is a significant improvement in the IIEF EF domain at the end of the 100 mg period, as compared to the baseline (Week 0) score. Sample size (N=115) provides more than 90% power to detect a change from baseline of 10 in the primary efficacy variable, assuming a standard deviation of 9, using the two-sided, single-sample t-test with significance level (alpha) of 0.05.p-value: <0.00195% CI: [10, 11.93]t-test, 2 sided
Secondary

International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6

IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 & 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6Week 2 (N=113)7.14 score on a scaleStandard Deviation 5.21
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6Week 4 (N=112)10.57 score on a scaleStandard Deviation 5.43
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6Week 6 (N=110)10.93 score on a scaleStandard Deviation 5.26
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6Week 6 Endpoint (N=112)10.95 score on a scaleStandard Deviation 5.21
Comparison: Week 2 minus baselinep-value: <0.00195% CI: [6.17, 8.11]t-test, 2 sided
Comparison: Week 4 minus baselinep-value: <0.00195% CI: [9.56, 11.59]t-test, 2 sided
Comparison: Week 6 minus baselinep-value: <0.00195% CI: [9.93, 11.92]t-test, 2 sided
Comparison: Week 6 endpoint minus baselinep-value: <0.00195% CI: [9.97, 11.92]t-test, 2 sided
Secondary

International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2

IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 & 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2Week 4 (N=112)3.48 score on scaleStandard Deviation 3.97
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2Week 6 (N=110)3.88 score on scaleStandard Deviation 4.38
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2Week 6 LOCF (N=112)3.86 score on scaleStandard Deviation 4.35
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2Week 6 Endpoint (N=112)3.86 score on scaleStandard Deviation 4.35
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [2.74, 4.23]t-test, 2 sided
Comparison: Week 6 minus Week 2 For the secondary outcome, the change in IIEF-EF domain from the end of 50 mg period (Week 2) to the end of 100 mg period (Week 6), the sample size (N=115) provides more than 80% power to detect a mean change of 1.75 points, assuming a standard deviation of 6, using the two-sided, single sample t-test with significance level (alpha) of 0.05p-value: <0.00195% CI: [3.05, 4.71]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2 For the secondary outcome, the change in IIEF-EF domain from the end of 50 mg period (Week 2) to the end of 100 mg period (Week 6), the sample size (N=115) provides more than 80% power to detect a mean change of 1.75 points, assuming a standard deviation of 6, using the two-sided, single sample t-test with significance level (alpha) of 0.05p-value: <0.00195% CI: [3.04, 4.67]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2 For the secondary outcome, the change in IIEF-EF domain from the end of 50 mg period (Week 2) to the end of 100 mg period (Week 6), the sample size (N=115) provides more than 80% power to detect a mean change of 1.75 points, assuming a standard deviation of 6, using the two-sided, single sample t-test with significance level (alpha) of 0.05p-value: <0.00195% CI: [3.04, 4.67]t-test, 2 sided
Secondary

International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Baseline

IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.

Time frame: Week 2, Week 4, and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From BaselineWeek 2 (N=113)3.18 score on scaleStandard Deviation 2.42
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From BaselineWeek 4 (N=112)4.38 score on scaleStandard Deviation 2.39
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From BaselineWeek 6 (N=110)4.73 score on scaleStandard Deviation 2.53
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From BaselineWeek 6 LOCF (N=113)4.70 score on scaleStandard Deviation 2.52
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From BaselineWeek 6 Endpoint (N=112)4.72 score on scaleStandard Deviation 2.52
Comparison: Week 2 minus Baselinep-value: <0.00195% CI: [2.73, 3.63]t-test, 2 sided
Comparison: Week 4 minus Baselinep-value: <0.00195% CI: [3.94, 4.83]t-test, 2 sided
Comparison: Week 6 minus Baselinep-value: <0.00195% CI: [4.25, 5.21]t-test, 2 sided
Comparison: Week 6 LOCF minus Baselinep-value: <0.00195% CI: [4.23, 5.17]t-test, 2 sided
Comparison: Week 6 Endpoint minus Baselinep-value: <0.00195% CI: [4.25, 5.19]t-test, 2 sided
Secondary

International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2

IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2Week 4 (N=112)1.20 score on scaleStandard Deviation 2.1
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2Week 6 (N=110)1.54 score on scaleStandard Deviation 2.2
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2Week 6 LOCF (N=112)1.54 score on scaleStandard Deviation 2.19
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2Week 6 Endpoint (N=112)1.54 score on scaleStandard Deviation 2.19
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [0.8, 1.59]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: <0.00195% CI: [1.12, 1.95]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [1.13, 1.95]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [1.13, 1.95]t-test, 2 sided
Secondary

International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Baseline

IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From BaselineWeek 2 (N=113)1.89 score on scaleStandard Deviation 2.4
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From BaselineWeek 4 (N=112)2.46 score on scaleStandard Deviation 2.32
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From BaselineWeek 6 (N=110)2.59 score on scaleStandard Deviation 2.44
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From BaselineWeek 6 LOCF (N=113)2.63 score on scaleStandard Deviation 2.45
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From BaselineWeek 6 Endpoint (N=112)2.59 score on scaleStandard Deviation 2.42
Comparison: Week 2 minus Baselinep-value: <0.00195% CI: [1.45, 2.34]t-test, 2 sided
Comparison: Week 4 minus Baselinep-value: <0.00195% CI: [2.02, 2.89]t-test, 2 sided
Comparison: Week 6 minus Baselinep-value: <0.00195% CI: [2.13, 3.05]t-test, 2 sided
Comparison: Week 6 LOCF minus Baselinep-value: <0.00195% CI: [2.17, 3.08]t-test, 2 sided
Comparison: Week 6 Endpoint minus Baselinep-value: <0.00195% CI: [2.14, 3.04]t-test, 2 sided
Secondary

International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2

IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2Week 4 (N=112)0.61 score on scaleStandard Deviation 1.51
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2Week 6 (N=110)0.75 score on scaleStandard Deviation 1.46
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2Week 6 LOCF (N=112)0.74 score on scaleStandard Deviation 1.45
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2Week 6 Endpoint (N=112)0.74 score on scaleStandard Deviation 1.45
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [0.47, 1.01]t-test, 2 sided
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [0.32, 0.89]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: <0.00195% CI: [0.47, 1.02]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [0.47, 1.01]t-test, 2 sided
Secondary

International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Baseline

IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From BaselineWeek 2 (N=113)2.73 score on scaleStandard Deviation 2.38
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From BaselineWeek 4 (N=112)3.67 score on scaleStandard Deviation 2.49
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From BaselineWeek 6 (N=110)3.92 score on scaleStandard Deviation 2.52
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From BaselineWeek 6 LOCF (N=113)3.91 score on scaleStandard Deviation 2.53
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From BaselineWeek 6 Endpoint (N=112)3.89 score on scaleStandard Deviation 2.53
Comparison: Week 2 minus Baselinep-value: <0.00195% CI: [2.28, 3.17]t-test, 2 sided
Comparison: Week 4 minus Baselinep-value: <0.00195% CI: [3.2, 4.14]t-test, 2 sided
Comparison: Week 6 minus Baselinep-value: <0.00195% CI: [3.44, 4.4]t-test, 2 sided
Comparison: Week 6 LOCF minus Baselinep-value: <0.00195% CI: [3.44, 4.38]t-test, 2 sided
Comparison: Week 6 Endpoint minus Baselinep-value: <0.00195% CI: [3.42, 4.37]t-test, 2 sided
Secondary

International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2

IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2Week 4 (N=112)0.97 score on scaleStandard Deviation 1.88
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2Week 6 (N=110)1.21 score on scaleStandard Deviation 1.92
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2Week 6 LOCF (N=112)1.20 score on scaleStandard Deviation 1.9
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2Week 6 Endpoint (N=112)1.20 score on scaleStandard Deviation 1.9
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [0.62, 1.32]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: <0.00195% CI: [0.85, 1.57]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [0.84, 1.55]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [0.84, 1.55]t-test, 2 sided
Secondary

International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Baseline

IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From BaselineWeek 2 (N=113)1.43 score on scaleStandard Deviation 1.87
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From BaselineWeek 4 (N=112)2.00 score on scaleStandard Deviation 1.86
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From BaselineWeek 6 (N=110)2.25 score on scaleStandard Deviation 1.91
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From BaselineWeek 6 LOCF (N=113)2.26 score on scaleStandard Deviation 1.94
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From BaselineWeek 6 Endpoint (N=112)2.28 score on scaleStandard Deviation 1.93
Comparison: Week 2 minus Baselinep-value: <0.00195% CI: [1.09, 1.78]t-test, 2 sided
Comparison: Week 4 minus Baselinep-value: <0.00195% CI: [1.65, 2.35]t-test, 2 sided
Comparison: Week 6 minus Baselinep-value: <0.00195% CI: [1.89, 2.62]t-test, 2 sided
Comparison: Week 6 LOCF minus Baselinep-value: <0.00195% CI: [1.9, 2.62]t-test, 2 sided
Comparison: Week 6 Endpoint minus Baselinep-value: <0.00195% CI: [1.91, 2.64]t-test, 2 sided
Secondary

International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2

IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2Week 4 (N=112)0.55 score on scaleStandard Deviation 1.41
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2Week 6 (N=110)0.81 score on scaleStandard Deviation 1.47
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2Week 6 LOCF (N=112)0.83 score on scaleStandard Deviation 1.49
Open Label Sildenafil CitrateInternational Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2Week 6 Endpoint (N=112)0.83 score on scaleStandard Deviation 1.49
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [0.29, 0.82]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: <0.00195% CI: [0.53, 1.09]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [0.55, 1.11]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [0.55, 1.11]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Baseline

Mean change: mean change at each visit minus mean at baseline. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From BaselineGrade 1 (Week 2) N=103-12.58 per-patient percentageStandard Deviation 37.77
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From BaselineGrade 1 (Week 4) N=101-20.55 per-patient percentageStandard Deviation 35.04
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From BaselineGrade 1 (Week 6) N=98-22.53 per-patient percentageStandard Deviation 36.64
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From BaselineGrade 1 (Week 6 LOCF) N=103-21.44 per-patient percentageStandard Deviation 36.06
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From BaselineGrade 1 (Week 6 Endpoint) N=101-21.86 per-patient percentageStandard Deviation 36.29
Comparison: Week 2 minus baselinep-value: 0.00195% CI: [-19.96, -5.2]t-test, 2 sided
Comparison: Week 4 minus baselinep-value: <0.00195% CI: [-27.47, -13.64]t-test, 2 sided
Comparison: Week 6 minus baselinep-value: <0.00195% CI: [-29.88, -15.18]t-test, 2 sided
Comparison: Week 6 LOCF minus baselinep-value: <0.00195% CI: [-28.49, -14.39]t-test, 2 sided
Comparison: Week 6 Endpoint minus baselinep-value: <0.00195% CI: [-29.03, -14.7]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2

Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2Grade 1 (Week 4) N=110-6.79 per-patient percentageStandard Deviation 22.58
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2Grade 1 (Week 6) N=107-6.85 per-patient percentageStandard Deviation 23.02
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2Grade 1 (Week 6 LOCF) N=112-7.43 per-patient percentageStandard Deviation 24.2
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2Grade 1 (Week 6 Endpoint) N=110-7.57 per-patient percentageStandard Deviation 24.4
Comparison: Week 4 minus Week 2p-value: 0.002195% CI: [-11.06, -2.52]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: 0.002795% CI: [-11.26, -2.43]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: 0.001595% CI: [-11.97, -2.9]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: 0.001595% CI: [-12.18, -2.96]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline

Mean change: mean change at each visit minus mean at baseline. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 2 (Week 2) N=103-9.87 Per-patient percentageStandard Deviation 34.44
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 2 (Week 4) N=101-11.74 Per-patient percentageStandard Deviation 32.8
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 2 (Week 6) N=98-12.78 Per-patient percentageStandard Deviation 33.56
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 2 (Week 6 LOCF) N=103-13.13 Per-patient percentageStandard Deviation 33.94
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 2 (Week 6 Endpoint) N=101-12.40 Per-patient percentageStandard Deviation 33.13
Comparison: Week 2 minus baselinep-value: 0.004595% CI: [-16.6, -3.14]t-test, 2 sided
Comparison: Week 4 minus baselinep-value: <0.00195% CI: [-18.22, -5.27]t-test, 2 sided
Comparison: Week 6 minus baselinep-value: <0.00195% CI: [-19.51, -6.05]t-test, 2 sided
Comparison: Week 6 LOCF minus baselinep-value: <0.00195% CI: [-19.76, -6.5]t-test, 2 sided
Comparison: Week 6 Endpoint minus baselinep-value: <0.00195% CI: [-18.94, -5.86]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2

Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 2 (Week 4) N=110-2.39 per-patient percentageStandard Deviation 22
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 2 (Week 6) N=107-1.91 per-patient percentageStandard Deviation 20.73
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 2 (Week 6 LOCF) N=112-2.71 per-patient percentageStandard Deviation 22.28
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 2 (Week 6 Endpoint) N=110-2.76 per-patient percentageStandard Deviation 22.48
Comparison: Week 4 minus Week 2p-value: 0.256795% CI: [-6.55, 1.77]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: 0.343595% CI: [-5.88, 2.07]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: 0.295% CI: [-6.89, 1.46]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: 0.295% CI: [-7.01, 1.48]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline

Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (3= hard enough for penetration \[but not completely hard\]) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 3 (Week 2) N=103-10.82 per-patient percentageStandard Deviation 56.75
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 3 (Week 4) N=101-29.16 per-patient percentageStandard Deviation 59.81
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 3 (Week 6) N=98-30.79 per-patient percentageStandard Deviation 60.9
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 3 (Week 6 LOCF) N=103-30.27 per-patient percentageStandard Deviation 61.7
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 3 (Week 6 Endpoint) N=101-30.87 per-patient percentageStandard Deviation 60.54
Comparison: Week 2 minus baselinep-value: 0.055895% CI: [-21.91, 0.27]t-test, 2 sided
Comparison: Week 4 minus baselinep-value: <0.00195% CI: [-40.96, -17.35]t-test, 2 sided
Comparison: Week 6 minus baselinep-value: <0.00195% CI: [-43, -18.58]t-test, 2 sided
Comparison: Week 6 LOCF minus baselinep-value: <0.00195% CI: [-42.33, -18.21]t-test, 2 sided
Comparison: Week 6 Endpoint minus baselinep-value: <0.00195% CI: [-42.82, -18.92]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2

Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (3= hard enough for penetration \[but not completely hard\]) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 1 (Week 4) N=110-18.36 per-patient percentageStandard Deviation 46.03
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 1 (Week 6) N=107-22.16 per-patient percentageStandard Deviation 45.24
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 1 (Week 6 LOCF) N=112-20.28 per-patient percentageStandard Deviation 45.86
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 1 (Week 6 Endpoint) N=110-20.65 per-patient percentageStandard Deviation 46.2
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [-27.05, -9.66]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: <0.00195% CI: [-30.84, -13.49]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [-28.87, -11.69]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [-29.38, -11.92]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline

Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (hard enough for penetration \[but not completely hard\]) or 4 (completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 3 or 4 (Week 2) N=10322.45 per-patient percentageStandard Deviation 46.1
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 3 or 4 (Week 4) N=10132.30 per-patient percentageStandard Deviation 42.15
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 3 or 4 (Week 6) N=9835.31 per-patient percentageStandard Deviation 43.52
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 3 or 4 (Week 6 LOCF) N=10334.57 per-patient percentageStandard Deviation 43.48
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 3 or 4 (Week 6 Endpoint) N=10134.26 per-patient percentageStandard Deviation 43.29
Comparison: Week 2 minus baselinep-value: <0.00195% CI: [13.44, 31.46]t-test, 2 sided
Comparison: Week 4 minus baselinep-value: <0.00195% CI: [23.97, 40.62]t-test, 2 sided
Comparison: Week 6 minus baselinep-value: <0.00195% CI: [26.59, 44.04]t-test, 2 sided
Comparison: Week 6 LOCF minus baselinep-value: <0.00195% CI: [26.07, 43.07]t-test, 2 sided
Comparison: Week 6 Endpoint minus baselinep-value: <0.00195% CI: [25.72, 42.81]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2

Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (hard enough for penetration \[but not completely hard\]) or 4 (completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 3 or 4 (Week 4) N=1109.18 per-patient percentageStandard Deviation 29.45
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 3 or 4 (Week 6) N=1078.75 per-patient percentageStandard Deviation 29.26
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 3 or 4 (Week 6 LOCF ) N=11210.15 per-patient percentageStandard Deviation 31.11
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 3 or 4 (Week 6 Endpoint ) N=11010.33 per-patient percentageStandard Deviation 31.36
Comparison: Week 4 minus Week 2p-value: 0.001495% CI: [3.61, 14.74]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: 0.002595% CI: [3.15, 14.36]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [4.32, 15.97]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [4.41, 16.26]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline

Mean change: mean change at each visit minus mean at baseline. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 4 (Week 2) N=10333.27 per-patient percentageStandard Deviation 41.43
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 4 (Week 4) N=10161.45 per-patient percentageStandard Deviation 44.77
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 4 (Week 6) N=9866.10 per-patient percentageStandard Deviation 45.15
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 4 (Week 6 LOCF) N=10364.84 per-patient percentageStandard Deviation 45.7
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From BaselineGrade 4 (Week 6 Endpoint) N=10165.13 per-patient percentageStandard Deviation 45.56
Comparison: Week 2 minus baselinep-value: <0.00195% CI: [25.17, 41.36]t-test, 2 sided
Comparison: Week 4 minus baselinep-value: <0.00195% CI: [52.61, 70.29]t-test, 2 sided
Comparison: Week 6 minus baselinep-value: <0.00195% CI: [57.05, 75.16]t-test, 2 sided
Comparison: Week 6 LOCF minus baselinep-value: <0.00195% CI: [55.91, 73.77]t-test, 2 sided
Comparison: Week 6 Endpoint minus baselinep-value: <0.00195% CI: [56.14, 74.12]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2

Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 4 (Week 4) N=11027.53 per-patient percentageStandard Deviation 40.19
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 4 (Week 6) N=10730.92 per-patient percentageStandard Deviation 41.9
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 4 (Week 6 LOCF) N=11230.43 per-patient percentageStandard Deviation 41.88
Open Label Sildenafil CitrateMean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2Grade 4 (Week 6 Endpoint) N=11030.98 per-patient percentageStandard Deviation 42.06
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [19.94, 35.13]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: <0.00195% CI: [22.89, 38.95]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [22.59, 38.27]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [23.04, 38.93]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2

Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to Question 1 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 1 \[Were you able to achieve at least some erection (some enlargement of the penis)?\] = Yes) / (number of occasions where Question 1 was answered Yes or No)

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2Question 1 (Week 4) N=1111.37 per-patient percentageStandard Deviation 14.85
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2Question 1 (Week 6) N=1083.12 per-patient percentageStandard Deviation 14.26
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2Question 1 (Week 6 LOCF) N=1132.98 per-patient percentageStandard Deviation 13.95
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2Question 1 (Week 6 Endpoint) N=1113.04 per-patient percentageStandard Deviation 14.07
Comparison: Week 4 minus Week 2p-value: 0.332495% CI: [-1.42, 4.17]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: 0.024995% CI: [0.4, 5.84]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: 0.024995% CI: [0.37, 5.58]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: 0.024995% CI: [0.39, 5.68]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From Baseline

Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to Question 1 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 1 \[Were you able to achieve at least some erection (some enlargement of the penis)?\] = Yes) / (number of occasions where Question 1 was answered Yes or No)

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From BaselineQuestion 1 (Week 2) N=1108.84 per-patient percentageStandard Deviation 28.7
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From BaselineQuestion 1 (Week 4) N=10810.18 per-patient percentageStandard Deviation 27.51
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From BaselineQuestion 1 (Week 6) N=10512.29 per-patient percentageStandard Deviation 28.88
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From BaselineQuestion 1 (Week 6 LOCF) N=11011.96 per-patient percentageStandard Deviation 28.33
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From BaselineQuestion 1 (Week 6 Endpoint) N=10811.95 per-patient percentageStandard Deviation 28.55
Comparison: Week 2 minus baselinep-value: 0.001695% CI: [3.42, 14.26]t-test, 2 sided
Comparison: Week 4 minus baselinep-value: <0.00195% CI: [4.93, 15.43]t-test, 2 sided
Comparison: Week 6 minus baselinep-value: <0.00195% CI: [6.7, 17.88]t-test, 2 sided
Comparison: Week 6 LOCF minus baselinep-value: <0.00195% CI: [6.61, 17.32]t-test, 2 sided
Comparison: Week 6 Endpoint minus baselinep-value: <0.00195% CI: [6.51, 17.4]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Baseline

Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 2 \[Were you able to insert your penis into your partner's vagina?\] = Yes) / (number of occasions where SEP Question 2 was answered Yes or No).

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From BaselineQuestion 2 (Week 2) N=10215.37 per-patient percentageStandard Deviation 30.51
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From BaselineQuestion 2 (Week 4) N=10017.15 per-patient percentageStandard Deviation 32.22
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From BaselineQuestion 2 (Week 6) N=9718.22 per-patient percentageStandard Deviation 32.44
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From BaselineQuestion 2 (Week 6 LOCF) N=10217.33 per-patient percentageStandard Deviation 31.87
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From BaselineQuestion 2 (Week 6 Endpoint) N=10017.68 per-patient percentageStandard Deviation 32.1
Comparison: Week 2 minus baselinep-value: <0.00195% CI: [9.38, 21.36]t-test, 2 sided
Comparison: Week 4 minus baselinep-value: <0.00195% CI: [10.76, 23.55]t-test, 2 sided
Comparison: Week 6 minus baselinep-value: <0.00195% CI: [11.68, 24.76]t-test, 2 sided
Comparison: Week 6 LOCF minus baselinep-value: <0.00195% CI: [11.07, 23.59]t-test, 2 sided
Comparison: Week 6 Endpoint minus baselinep-value: <0.00195% CI: [11.31, 24.04]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2

Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 2 \[Were you able to insert your penis into your partner's vagina?\] = Yes) / (number of occasions where SEP Question 2 was answered Yes or No).

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2Question 2 (Week 4) N=1101.46 per-patient percentageStandard Deviation 9.41
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2Question 2 (Week 6) N=1071.18 per-patient percentageStandard Deviation 12.33
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2Question 2 (Week 6 LOCF) N=1121.13 per-patient percentageStandard Deviation 12.05
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2Question 2 (Week 6 Endpoint) N=1101.15 per-patient percentageStandard Deviation 12.16
Comparison: Week 4 minus Week 2p-value: 0.106195% CI: [-0.32, 3.24]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: 0.323795% CI: [-1.18, 3.54]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: 0.323695% CI: [-1.13, 3.38]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: 0.323695% CI: [-1.15, 3.45]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2

Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2Question 3 (Week 4) N=11013.56 per-patient percentageStandard Deviation 30.89
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2Question 3 (Week 6) N=10714.25 per-patient percentageStandard Deviation 31.31
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2Question 3 (Week 6 LOCF) N=11214.51 per-patient percentageStandard Deviation 31.77
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2Question 3 (Week 6 Endpoint) N=11014.77 per-patient percentageStandard Deviation 32
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [7.72, 19.4]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: <0.00195% CI: [8.25, 20.25]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [8.56, 20.46]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [8.72, 20.82]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From Baseline

Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From BaselineQuestion 3 (Week 2) N=10256.96 per-patient percentageStandard Deviation 38.93
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From BaselineQuestion 3 (Week 4) N=10070.78 per-patient percentageStandard Deviation 35.46
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From BaselineQuestion 3 (Week 6) N=9771.23 per-patient percentageStandard Deviation 35.79
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From BaselineQuestion 3 (Week 6 LOCF) N=10272.15 per-patient percentageStandard Deviation 35.41
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From BaselineQuestion 3 (Week 6 Endpoint) N=10071.60 per-patient percentageStandard Deviation 35.55
Comparison: Week 2 minus baselinep-value: <0.00195% CI: [49.31, 64.6]t-test, 2 sided
Comparison: Week 4 minus baselinep-value: <0.00195% CI: [63.74, 77.81]t-test, 2 sided
Comparison: Week 6 minus baselinep-value: <0.00195% CI: [64.02, 78.45]t-test, 2 sided
Comparison: Week 6 LOCF minus baselinep-value: <0.00195% CI: [65.2, 79.11]t-test, 2 sided
Comparison: Week 6 Endpoint minus baselinep-value: <0.00195% CI: [64.54, 78.65]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Baseline

Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Q3 based on attempts with sexual stimulation (SS): 100\* (number of attempts with SS where SEP Q3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)

Time frame: Week 2, Week 4, and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From BaselineWeek 2 (N=102)56.96 per-patient percentageStandard Deviation 38.93
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From BaselineWeek 4 (N=100)70.78 per-patient percentageStandard Deviation 35.46
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From BaselineWeek 6 (N=97)71.23 per-patient percentageStandard Deviation 35.79
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From BaselineWeek 6 LOCF (N=102)72.15 per-patient percentageStandard Deviation 35.41
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From BaselineWeek 6 Endpoint (N=100)71.60 per-patient percentageStandard Deviation 35.55
Comparison: Week 2 minus Baselinep-value: <0.00195% CI: [49.31, 64.6]t-test, 2 sided
Comparison: Week 4 minus baselinep-value: <0.00195% CI: [63.74, 77.81]t-test, 2 sided
Comparison: Week 6 minus baselinep-value: <0.00195% CI: [64.02, 78.45]t-test, 2 sided
Comparison: Week 6 LOCF minus baselinep-value: <0.00195% CI: [65.2, 79.11]t-test, 2 sided
Comparison: Week 6 Endpoint minus baselinep-value: <0.00195% CI: [64.54, 78.65]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2

Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Q3 based on attempts with sexual stimulation (SS): 100\* (number of attempts with SS where SEP Q3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2Week 4 (N=110)13.56 per-patient percentageStandard Deviation 30.89
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2Week 6 (N=107)14.25 per-patient percentageStandard Deviation 31.31
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2Week 6 LOCF (N=112)14.51 per-patient percentageStandard Deviation 31.77
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2Week 6 Endpoint (N=110)14.77 per-patient percentageStandard Deviation 32
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [7.72, 19.4]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: <0.00195% CI: [8.25, 20.25]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [8.56, 20.46]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [8.72, 20.82]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Baseline

Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 4 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 4 \[Were you satisfied with the hardness of your erection?\] = Yes) / (number of occasions where SEP Question 4 was answered Yes or No).

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From BaselineQuestion 4 (Week 2) N=10258.58 per-patient percentageStandard Deviation 41.24
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From BaselineQuestion 4 (Week 4) N=10076.29 per-patient percentageStandard Deviation 37.21
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From BaselineQuestion 4(Week 6) N=9777.69 per-patient percentageStandard Deviation 37.26
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From BaselineQuestion 4 (Week 6 LOCF) N=10278.79 per-patient percentageStandard Deviation 36.65
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From BaselineQuestion 4 (Week 6 Endpoint) N=10078.36 per-patient percentageStandard Deviation 36.89
Comparison: Week 2 minus baselinep-value: <0.00195% CI: [50.48, 66.68]t-test, 2 sided
Comparison: Week 4 minus baselinep-value: <0.00195% CI: [68.9, 83.67]t-test, 2 sided
Comparison: Week 6 minus baselinep-value: <0.00195% CI: [70.18, 85.21]t-test, 2 sided
Comparison: Week 6 LOCF minus baselinep-value: <0.00195% CI: [71.59, 85.99]t-test, 2 sided
Comparison: Week 6 Endpoint minus baselinep-value: <0.00195% CI: [71.04, 85.68]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2

Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 4 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 4 \[Were you satisfied with the hardness of your erection?\] = Yes) / (number of occasions where SEP Question 4 was answered Yes or No).

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2Question 4 (Week 4) N=11017.90 per-patient percentageStandard Deviation 36.63
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2Question 4 (Week 6) N=10719.50 per-patient percentageStandard Deviation 36.84
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2Question 4 (Week 6 LOCF) N=11219.52 per-patient percentageStandard Deviation 36.99
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2Question 4 (Week 6 Endpoint) N=11019.88 per-patient percentageStandard Deviation 37.23
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [10.98, 24.83]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: <0.00195% CI: [12.44, 26.56]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [12.59, 26.45]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [12.84, 26.91]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Baseline

Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 5 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 5 \[Were you satisfied with this sexual encounter?\] = Yes) / (number of occasions where SEP Question 5 was answered Yes or No)

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From BaselineQuestion 5 (Week 2) N=10157.34 per-patient percentageStandard Deviation 42.6
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From BaselineQuestion 5 (Week 4) N=10070.72 per-patient percentageStandard Deviation 40.3
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From BaselineQuestion 5 (Week 6) N=9770.63 per-patient percentageStandard Deviation 40.78
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From BaselineQuestion 5 (Week 6 LOCF) N=10272.07 per-patient percentageStandard Deviation 40.27
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From BaselineQuestion 5 (Week 6 Endpoint) N=10071.51 per-patient percentageStandard Deviation 40.48
Comparison: Week 2 minus baselinep-value: <0.00195% CI: [48.93, 65.75]t-test, 2 sided
Comparison: Week 4 minus baselinep-value: <0.00195% CI: [62.72, 78.71]t-test, 2 sided
Comparison: Week 6 minus baselinep-value: <0.00195% CI: [62.41, 78.85]t-test, 2 sided
Comparison: Week 6 LOCF minus baselinep-value: <0.00195% CI: [64.16, 79.98]t-test, 2 sided
Comparison: Week 6 Endpoint minus baselinep-value: <0.00195% CI: [63.48, 79.55]t-test, 2 sided
Secondary

Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2

Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 5 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 5 \[Were you satisfied with this sexual encounter?\] = Yes) / (number of occasions where SEP Question 5 was answered Yes or No)

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2Question 5 (Week 4) N=10913.10 per-patient percentageStandard Deviation 29.11
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2Question 5 (Week 6) N=10614.11 per-patient percentageStandard Deviation 32.53
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2Question 5 (Week 6 LOCF) N=11113.47 per-patient percentageStandard Deviation 31.92
Open Label Sildenafil CitrateMean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2Question 5 (Week 6 Endpoint) N=10913.72 per-patient percentageStandard Deviation 32.16
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [7.58, 18.63]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: <0.00195% CI: [7.84, 20.37]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [7.47, 19.47]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [7.61, 19.82]t-test, 2 sided
Secondary

Quality of Erection Questionnaire (QEQ): Total Score - Change From Baseline

QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.

Time frame: Week 2, Week 4, and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateQuality of Erection Questionnaire (QEQ): Total Score - Change From BaselineWeek 2 (N=113)32.71 score on scaleStandard Deviation 25.36
Open Label Sildenafil CitrateQuality of Erection Questionnaire (QEQ): Total Score - Change From BaselineWeek 4 (N=112)46.21 score on scaleStandard Deviation 26.27
Open Label Sildenafil CitrateQuality of Erection Questionnaire (QEQ): Total Score - Change From BaselineWeek 6 (N=110)45.53 score on scaleStandard Deviation 26.96
Open Label Sildenafil CitrateQuality of Erection Questionnaire (QEQ): Total Score - Change From BaselineWeek 6 LOCF (N=113)45.28 score on scaleStandard Deviation 27.01
Open Label Sildenafil CitrateQuality of Erection Questionnaire (QEQ): Total Score - Change From BaselineWeek 6 Endpoint (N=112)45.05 score on scaleStandard Deviation 27.02
Comparison: Week 2 minus Baselinep-value: <0.00195% CI: [27.98, 37.43]t-test, 2 sided
Comparison: Week 4 minus Baselinep-value: <0.00195% CI: [41.29, 51.12]t-test, 2 sided
Comparison: Week 6 minus Baselinep-value: <0.00195% CI: [40.44, 50.63]t-test, 2 sided
Comparison: Week 6 LOCF minus Baselinep-value: <0.00195% CI: [40.25, 50.31]t-test, 2 sided
Comparison: Week 6 Endpoint minus Baselinep-value: <0.00195% CI: [39.99, 50.11]t-test, 2 sided
Secondary

Quality of Erection Questionnaire (QEQ): Total Score- Change From Week 2

QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.

Time frame: Week 4 and Week 6

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateQuality of Erection Questionnaire (QEQ): Total Score- Change From Week 2Week 6 (N=110)13.07 score on scaleStandard Deviation 24.25
Open Label Sildenafil CitrateQuality of Erection Questionnaire (QEQ): Total Score- Change From Week 2Week 4 (N=112)13.84 score on scaleStandard Deviation 21.1
Open Label Sildenafil CitrateQuality of Erection Questionnaire (QEQ): Total Score- Change From Week 2Week 6 LOCF (N=112)12.69 score on scaleStandard Deviation 24.26
Open Label Sildenafil CitrateQuality of Erection Questionnaire (QEQ): Total Score- Change From Week 2Week 6 Endpoint (N=112)12.69 score on scaleStandard Deviation 24.26
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [9.89, 17.79]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: <0.00195% CI: [8.49, 17.65]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [8.14, 17.23]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [8.14, 17.23]t-test, 2 sided
Secondary

Sexual Experience Questionnaire (Sex-Q): Erection Domain - Change From Baseline

Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.

Time frame: Week 2, Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Erection Domain - Change From BaselineWeek 2 (N=113)5.41 score on scaleStandard Deviation 4.4
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Erection Domain - Change From BaselineWeek 4 (N=112)8.85 score on scaleStandard Deviation 4.96
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Erection Domain - Change From BaselineWeek 6 (N=110)9.21 score on scaleStandard Deviation 5.19
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Erection Domain - Change From BaselineWeek 6 LOCF (N=113)9.28 score on scaleStandard Deviation 5.14
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Erection Domain - Change From BaselineWeek 6 Endpoint (N=112)9.25 score on scaleStandard Deviation 5.15
Comparison: Week 2 minus Baselinep-value: <0.00195% CI: [4.59, 6.23]t-test, 2 sided
Comparison: Week 4 minus Baselinep-value: <0.00195% CI: [7.92, 9.78]t-test, 2 sided
Comparison: Week 6 minus Baselinep-value: <0.00195% CI: [8.23, 10.19]t-test, 2 sided
Comparison: Week 6 LOCF minus Baselinep-value: <0.00195% CI: [8.32, 10.24]t-test, 2 sided
Comparison: Week 6 Endpoint minus Baselinep-value: <0.00195% CI: [8.28, 10.22]t-test, 2 sided
Secondary

Sexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2

Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2Week 4 (N=112)3.51 score on scaleStandard Deviation 3.89
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2Week 6 (N=110)3.91 score on scaleStandard Deviation 4.41
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2Week 6 LOCF (N=112)3.91 score on scaleStandard Deviation 4.38
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2Week 6 Endpoint (N=112)3.91 score on scaleStandard Deviation 4.38
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [2.78, 4.24]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: <0.00195% CI: [3.08, 4.74]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [3.09, 4.73]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [3.09, 4.73]t-test, 2 sided
Secondary

Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Baseline

Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.

Time frame: Week 2, Week 4, and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From BaselineWeek 2 (N=112)2.79 score on scaleStandard Deviation 2.44
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From BaselineWeek 4 (N=111)4.23 score on scaleStandard Deviation 2.56
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From BaselineWeek 6 (N=108)4.74 score on scaleStandard Deviation 2.84
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From BaselineWeek 6 LOCF (N=111)4.78 score on scaleStandard Deviation 2.81
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From BaselineWeek 6 Endpoint (N=110)4.76 score on scaleStandard Deviation 2.82
Comparison: Week 2 minus Baselinep-value: <0.00195% CI: [2.33, 3.24]t-test, 2 sided
Comparison: Week 4 minus Baselinep-value: <0.00195% CI: [3.74, 4.71]t-test, 2 sided
Comparison: Week 6 minus Baselinep-value: <0.00195% CI: [4.2, 5.28]t-test, 2 sided
Comparison: Week 6 LOCF minus Baselinep-value: <0.00195% CI: [4.25, 5.31]t-test, 2 sided
Comparison: Week 6 Endpoint minus Baselinep-value: <0.00195% CI: [4.23, 5.3]t-test, 2 sided
Secondary

Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2

Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2Week 4 (N=112)1.49 score on scaleStandard Deviation 1.91
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2Week 6 (N=109)1.96 score on scaleStandard Deviation 2.08
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2Week 6 LOCF (N=111)1.98 score on scaleStandard Deviation 2.07
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2Week 6 Endpoint (N=111)1.98 score on scaleStandard Deviation 2.07
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [1.13, 1.85]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: <0.00195% CI: [1.57, 2.36]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [1.59, 2.37]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [1.59, 2.37]t-test, 2 sided
Secondary

Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Baseline

Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome

Time frame: Week 2, Week 4, and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From BaselineWeek 2 (N=113)6.68 score on scaleStandard Deviation 4.86
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From BaselineWeek 4 (N=112)9.94 score on scaleStandard Deviation 5.21
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From BaselineWeek 6 (N=108)10.59 score on scaleStandard Deviation 5.08
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From BaselineWeek 6 LOCF (N=111)10.63 score on scaleStandard Deviation 5.03
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From BaselineWeek 6 Endpoint (N=110)10.64 score on scaleStandard Deviation 5.06
Comparison: Week 2 minus Baselinep-value: <0.00195% CI: [5.77, 7.59]t-test, 2 sided
Comparison: Week 4 minus Baselinep-value: <0.00195% CI: [8.96, 10.91]t-test, 2 sided
Comparison: Week 6 minus Baselinep-value: <0.00195% CI: [9.62, 11.56]t-test, 2 sided
Comparison: Week 6 LOCF minus Baselinep-value: <0.00195% CI: [9.68, 11.58]t-test, 2 sided
Comparison: Week 6 Endpoint minus Baselinep-value: <0.00195% CI: [9.68, 11.59]t-test, 2 sided
Secondary

Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2

Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome

Time frame: Week 4 and Week 6

Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2

ArmMeasureGroupValue (MEAN)Dispersion
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2Week 4 (N=112)3.29 score on scaleStandard Deviation 4.1
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2Week 6 (N=108)4.03 score on scaleStandard Deviation 5.09
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2Week 6 LOCF (N=110)4.01 score on scaleStandard Deviation 5.04
Open Label Sildenafil CitrateSexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2Week 6 Endpoint (N=110)4.01 score on scaleStandard Deviation 5.04
Comparison: Week 4 minus Week 2p-value: <0.00195% CI: [2.52, 4.05]t-test, 2 sided
Comparison: Week 6 minus Week 2p-value: <0.00195% CI: [3.06, 5]t-test, 2 sided
Comparison: Week 6 LOCF minus Week 2p-value: <0.00195% CI: [3.06, 4.96]t-test, 2 sided
Comparison: Week 6 Endpoint minus Week 2p-value: <0.00195% CI: [3.06, 4.96]t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026